We engineer a patient’s own regulatory T cells (Tregs) to correct the immune dysfunction driving autoimmune disease, designed to act at the site of inflammation, not systemically.
Engineering Treg biology into precision cell therapy.
Decades of Nobel-winning research into immune tolerance, paired with proprietary manufacturing designed to preserve regulatory T cell (Treg) function.
Autoimmune disease is chronic. Most cell therapies aren’t.
We’re building a new generation of Treg therapy for the course of the disease, not just a single intervention.
Supporting patients who've run out of options.
We are initially focused on poly-refractory rheumatoid arthritis, where our lead program is designed for patients who have exhausted multiple treatment options yet continue to experience active disease.
No preconditioning. No added burden.
Our therapy is engineered to work without the preconditioning or hospitalization many cell therapies require. It is designed to support repeat treatment as chronic disease demands, without disrupting patients’ lives to deliver it.
Engineering immune tolerance, precisely where it’s needed.
From lead program to broader Treg pipeline.
Our lead proprietary program, SBT7101, is designed around a mechanism, not a single disease, and our broader pipeline reflects that same principle. Beyond our lead indication, we believe this platform has the potential to extend across additional autoimmune and inflammatory conditions where restoring immune tolerance may offer meaningful benefit.
Supporting patients who’ve run out of options.
Our initial focus is poly-refractory rheumatoid arthritis: patients who have exhausted multiple treatment options and continue to live with active disease. It’s the proving ground for a broader approach to restoring immune tolerance.
Careers at SonomaBio
Restoring immune tolerance requires more than innovative science. It demands disciplined execution across research, clinical development, and manufacturing. We’re building that team, united by a shared commitment to patients.